Dopamine and congestive heart failure: Pharmacology, clinical use, and precautions

P. Van de Borne, Virend Somers

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

It has been suggested that low dose dopamine (< 5 μg/kg/min) may have renal protective effects. There are, however, no randomized, double blind, placebo controlled studies to support these observations. The contribution of improvements in cardiac output (due to β1-adrenergic stimulation) to increases in renal blood flow, independent of changes in renal vasodilation, are unclear. There is little evidence to support any dopamine induced clinically significant improvement in renal function in the presence of diuretics. Given the limited evidence of benefits of low dose dopamine, potential adverse effects need to be recognized, particularly in patients with heart failure. Low dose dopamine induces hypoxemia in patients with heart failure by impairing both gas exchange and ventilatory responses and thus could precipitate respiratory decompensation in patients being weaned from ventilators. Sleep disordered breathing is highly prevalent in heart failure patients - the effects of dopamine induced chemoreflex inhibition may prove deleterious in this condition. We therefore believe that current knowledge of the risk/benefit ratio of the use of 'renal doses' of dopamine does not support its widespread use in patients with heart failure, particularly in those patients in whom respiratory function is compromised.

Original languageEnglish (US)
Pages (from-to)216-221
Number of pages6
JournalCongestive Heart Failure
Volume5
Issue number5
StatePublished - 1999

Fingerprint

Clinical Pharmacology
Dopamine
Heart Failure
Kidney
Renal Circulation
Sleep Apnea Syndromes
Mechanical Ventilators
Diuretics
Vasodilation
Cardiac Output
Adrenergic Agents
Gases
Odds Ratio
Placebos

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dopamine and congestive heart failure : Pharmacology, clinical use, and precautions. / Van de Borne, P.; Somers, Virend.

In: Congestive Heart Failure, Vol. 5, No. 5, 1999, p. 216-221.

Research output: Contribution to journalArticle

@article{cc0f5a0ca0ab45d2a4dd0f4ce0567e49,
title = "Dopamine and congestive heart failure: Pharmacology, clinical use, and precautions",
abstract = "It has been suggested that low dose dopamine (< 5 μg/kg/min) may have renal protective effects. There are, however, no randomized, double blind, placebo controlled studies to support these observations. The contribution of improvements in cardiac output (due to β1-adrenergic stimulation) to increases in renal blood flow, independent of changes in renal vasodilation, are unclear. There is little evidence to support any dopamine induced clinically significant improvement in renal function in the presence of diuretics. Given the limited evidence of benefits of low dose dopamine, potential adverse effects need to be recognized, particularly in patients with heart failure. Low dose dopamine induces hypoxemia in patients with heart failure by impairing both gas exchange and ventilatory responses and thus could precipitate respiratory decompensation in patients being weaned from ventilators. Sleep disordered breathing is highly prevalent in heart failure patients - the effects of dopamine induced chemoreflex inhibition may prove deleterious in this condition. We therefore believe that current knowledge of the risk/benefit ratio of the use of 'renal doses' of dopamine does not support its widespread use in patients with heart failure, particularly in those patients in whom respiratory function is compromised.",
author = "{Van de Borne}, P. and Virend Somers",
year = "1999",
language = "English (US)",
volume = "5",
pages = "216--221",
journal = "Prevention and Management of Congestive Heart Failure",
issn = "1079-7998",
publisher = "Le Jacq Communications, Inc.",
number = "5",

}

TY - JOUR

T1 - Dopamine and congestive heart failure

T2 - Pharmacology, clinical use, and precautions

AU - Van de Borne, P.

AU - Somers, Virend

PY - 1999

Y1 - 1999

N2 - It has been suggested that low dose dopamine (< 5 μg/kg/min) may have renal protective effects. There are, however, no randomized, double blind, placebo controlled studies to support these observations. The contribution of improvements in cardiac output (due to β1-adrenergic stimulation) to increases in renal blood flow, independent of changes in renal vasodilation, are unclear. There is little evidence to support any dopamine induced clinically significant improvement in renal function in the presence of diuretics. Given the limited evidence of benefits of low dose dopamine, potential adverse effects need to be recognized, particularly in patients with heart failure. Low dose dopamine induces hypoxemia in patients with heart failure by impairing both gas exchange and ventilatory responses and thus could precipitate respiratory decompensation in patients being weaned from ventilators. Sleep disordered breathing is highly prevalent in heart failure patients - the effects of dopamine induced chemoreflex inhibition may prove deleterious in this condition. We therefore believe that current knowledge of the risk/benefit ratio of the use of 'renal doses' of dopamine does not support its widespread use in patients with heart failure, particularly in those patients in whom respiratory function is compromised.

AB - It has been suggested that low dose dopamine (< 5 μg/kg/min) may have renal protective effects. There are, however, no randomized, double blind, placebo controlled studies to support these observations. The contribution of improvements in cardiac output (due to β1-adrenergic stimulation) to increases in renal blood flow, independent of changes in renal vasodilation, are unclear. There is little evidence to support any dopamine induced clinically significant improvement in renal function in the presence of diuretics. Given the limited evidence of benefits of low dose dopamine, potential adverse effects need to be recognized, particularly in patients with heart failure. Low dose dopamine induces hypoxemia in patients with heart failure by impairing both gas exchange and ventilatory responses and thus could precipitate respiratory decompensation in patients being weaned from ventilators. Sleep disordered breathing is highly prevalent in heart failure patients - the effects of dopamine induced chemoreflex inhibition may prove deleterious in this condition. We therefore believe that current knowledge of the risk/benefit ratio of the use of 'renal doses' of dopamine does not support its widespread use in patients with heart failure, particularly in those patients in whom respiratory function is compromised.

UR - http://www.scopus.com/inward/record.url?scp=0033452502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033452502&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033452502

VL - 5

SP - 216

EP - 221

JO - Prevention and Management of Congestive Heart Failure

JF - Prevention and Management of Congestive Heart Failure

SN - 1079-7998

IS - 5

ER -